TC BioPharm will collaborate with Scotia Biologics to develop proprietary CAR-T treatments for cancer and anti-viral indications
First CAR-T products will target solid tumours
Glasgow and Aberdeen UK, 08 May, 2018 – TC BioPharm Ltd (TCB) and Scotia Biologics announced today that they have formed a strategic collaboration to co-develop novel proprietary tumour-specific antibodies for TCB’s CAR-T platform.
Using Scotia’s unique, proven technology the two companies will develop a range of cancer-targeting single-chain antibodies, each of which can be formulated to treat a specific type of cancer. Antibodies developed by Scotia will be incorporated into TCB’s therapeutic ImmuniCAR® product range.
Based in Aberdeen, Scotia Biologics are an immuno-technology company that specialises in generating and developing antibodies and vaccines for clinical diagnostic and immuno-therapy applications on fee for service basis.
Scotia’s Chief Executive, Keith Charlton commented, “establishing this partnership with TCB enables Scotia to apply its antibody generation and engineering expertise to the exciting, rapidly growing field of CAR-T technology – promising to deliver new safe therapies for diseases that are difficult to treat with current antibody-based approaches. It also represents a new focus for the Company by investing in longer-term revenue generation.”
TCB’s ImmuniCAR® platform is built on unique properties of modified gamma delta (γδ) T cells to selectively target cancer whilst leaving healthy cells untouched. TCB intends to use this novel platform to develop new CAR-T based immunotherapies, with the aim of treating a broad range of cancers and major viral disease.
The collaboration between the two companies opens new therapeutic horizons, providing TCB with invaluable access to novel therapeutic targets previously untreatable using conventional CAR-T technology.
Having previously developed therapeutic antibodies for third-party customers, Scotia has realigned commercial focus into immuno-oncology and treatment of cancer patients with TCB.
Providing TC BioPharm with invaluable elements of the CAR-T manufacturing and supply-chain, the multi-million pound deal will provide Scotia Biologics with non-dilutive funds in the form of research funding, milestone payments related to clinical progress and royalties on sales.
TCB’s Chief Operating Officer, Angela Scott commented, “having built internal infrastructure to produce clinical-grade cell therapies; additional ability to create proprietary therapeutic antibodies combined with in-house lentiviral manufacture gives TCB all the tools to rapidly develop a broad platform of CAR-based treatments against a wide variety of cancer and anti-viral targets”.
TCB and Scotia will initially co-develop single-chain antibodies against GD2, Her2 and PSMA which are expressed in neuroblastoma, breast and prostate cancer respectively. TCB will also explore use of CD4 to target both lymphoblastic leukemia and HIV. This therapeutic approach will provide product development opportunities for the Company to either commercialise in-house or collaborate with third-party pharma partners.
TCB’s proprietary ImmuniCAR® platform uses the innate ability of gamma-delta T cells to target cancer. This additional tumour-recognition channel combines with the regular CAR channel to create a unique ToxFree™ CAR-T mechanism, negating damage to healthy tissue inflicted by many current CAR-T products, allowing the Company to develop a wide range of innovative safe therapies to treat a variety of tumour types.
The collaboration is TCB’s first inward partnering deal, representing a strong endorsement of Scotia Biologic’s approach to new antibody generation. Remarking on this significant commercial milestone, Chief Executive Dr Michael Leek iterated that, “the commercial partnership with Scotia Biologics represents strategic acquisition of a key technology in the production of proprietary next-generation, safe CAR-T therapies – by controlling both genetic and cellular aspects of the GMP manufacturing process, TCB can develop multiple products designed to improve patient health and quality of life“.
Chief Business Officer Dr Artin Moussavi added, “The enormous potential of CAR-T to offer life-saving therapies to all cancer patients is currently hampered by safety concerns and strong commercial focus on B cell malignancies alone. This partnership allows us to accelerate development of our CAR-T products for a broader range of novel cancer and infectious disease targets beyond the reach of existing immunotherapies”.
For more information regarding TC BioPharm, please contact Suzanne Clark at Smarts Communicate:
email@example.com / 0141 222 2040 / 07970 834354
Note to Editors
Headquartered in Edinburgh with facilities in Glasgow, London and Kawasaki (Greater Tokyo), TCB is a clinical stage biotechnology company leading the way gamma delta T cells are being used to treat cancer and serious viral disease. TCB has strategic collaborations with pharmaceutical, biotechnology and leading research institutions bringing its transformative cell therapies to clinic. In January 2015, TCB’s cell therapy manufacturing facility at Maxim Office Park in Glasgow was awarded a Manufacturer’s Authorisation for Investigational Medicinal Products MIA (IMP) which permits manufacture and release of Advanced Therapy Medicinal Products (ATMPs) for use in clinical trials.
TCB has developed a novel gamma-delta CAR T platform (ImmuniCAR®) where T cells are supercharged using gene-therapy to target and kill specific cancer types. ImmuniCAR® represents a truly disruptive, step-changing approach to the treatment of a wide variety of cancers with potential to overcome many of the safety problems previously seen with conventional early-generation CAR T products. TCB is developing CAR T products against a range of cancer antigens with the potential to target both solid and blood tumours.
ImmuniCAR and ToxFree are trademarks of TC BioPharm, Ltd.
Based in Aberdeen, Scotia Biologics was established in 2012 as a contract research organisation focusing on immuno-technologies. It uses the considerable experience of its scientific research team and proprietary phage-display technologies to generate high performance monoclonal antibodies from a variety of sources to often very difficult targets, with clinical diagnostic and immuno-therapeutic applications for clients in the UK and internationally. It also has an extensive and long-running program of vaccine development for an international biotech company to treat a variety of cancer indications.